Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.

It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.

[1] Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.

[2] (So they could concentrate on their other product catumaxomab (trade name Removab).

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.